Genitourinary Radiology: Page 7

Blue Earth buys therapeutic rights to rhPSMA technology
By AuntMinnieEurope.com staff writers
Bracco molecular imaging subsidiary Blue Earth Diagnostics has acquired exclusive, worldwide rights to therapeutic applications of radiohybrid prostate-specific membrane antigen (rhPSMA) technology developed by German radiopharmaceutical firm Scintomics and the Technical University of Munich.
January 4, 2021
2019 12 19 00 53 5252 Hands Shaking Deal 400
Machine learning helps identify cystic renal lesions
By Erik L. Ridley
A machine-learning model based on CT radiomics analysis has achieved excellent diagnostic performance in distinguishing benign from malignant complex cystic renal lesions, outperforming the current Bosniak classification system, Canadian and French investigators reported at the RSNA 2020 meeting.
December 6, 2020
2019 01 15 00 00 8588 Kidneys 400
German group refines PET technique for prostate cancer
By Brian Casey
Researchers from Essen have used a PET-based optical imaging method known as Cerenkov luminescence imaging to highlight the presence of cancer cells after prostate cancer surgery. They published their results in the October edition of the Journal of Nuclear Medicine.
October 12, 2020
2020 10 12 17 13 8441 2020 10 08 Cerenkov 20201012175532
Scottish team strives to speed up prostate MRI reporting
By Philip Ward
Radiologists in Scotland have adopted a rigorous approach to quality management to improve the scheduling and reporting of prebiopsy prostate MRI exams. They narrowly failed to meet their 2019 target of reporting 90% of all requested exams within 28 days, but feel they're heading the right way.
October 11, 2020
2018 10 15 20 04 2505 2018 10 16 Jfr Irm Multiparametrique Thumb
Moscow PET facilities make change to prostate scans
By AuntMinnieEurope.com staff writers
Providers of PET services in Moscow have started using a radiopharmaceutical agent, F-18 prostate-specific membrane antigen, for a more accurate diagnosis of prostate cancer, according to a statement issued by the Research and Practical Clinical Center of Diagnostics and Telemedicine Technologies in Russia.
October 4, 2020
2019 05 03 20 23 2154 Prostate 3 D 400
Post-treatment SPECT/CT monitors radionuclide dose
By Kate Madden Yee
A research group from the Peter MacCallum Cancer Center in Melbourne, Australia, has pioneered a technique that uses a follow-up SPECT/CT examination after radionuclide therapy to personalize the radiation dose delivered to a patient.
September 6, 2020
2018 07 20 22 27 4483 Australian Flag 400
ViewRay highlights results from prostate cancer study
By AuntMinnieEurope.com staff writers
Image-guided radiation therapy vendor ViewRay is highlighting the results of a clinical study on the use of its MR-guided radiation therapy technology for treating men with prostate cancer.
June 24, 2020
2019 09 17 17 11 0207 Viewray Astro 2019
ITM signs supply deals with Point Biopharma
By AuntMinnieEurope.com staff writers
German radiopharmaceutical group ITM Isotopen Technologien München has signed supply agreements with radiopharmaceutical Point Biopharma for ITM's EndolucinBeta radiopharmaceutical precursor.
June 23, 2020
2016 08 24 09 43 13 537 Hands Shaking V3 400
Exact Imaging taps EDAP as exclusive distributor
By AuntMinnieEurope.com staff writers
Ultrasound technology developer Exact Imaging has named French therapeutic ultrasound firm EDAP as the sole distributor of its ExactVu microultrasound system in the U.S. market.
June 22, 2020
2019 12 19 00 53 5252 Hands Shaking Deal 400
Europe achieves growing consensus on prostate MRI
By Philip Ward
A group of expert radiologists and urologists have released new recommendations on quality issues in prostate MRI, covering acquisition, reporting, training and education, and experience prerequisites. The consensus paper has the support of the European Society of Urogenital Radiology and European Association of Urology.
May 26, 2020
2020 05 27 16 55 1679 2020 27 05 Mri Insider Prostate Mri Dce
Blue Earth Diagnostics brings Axumin to Slovakia
By AuntMinnieEurope.com staff writers
Molecular imaging company Blue Earth Diagnostics has completed the first commercial delivery of its Axumin (fluciclovine F-18) PET radiopharmaceutical in Slovakia.
April 21, 2020
2020 04 22 18 47 9460 Business Men Handshake 400
PSMA-PET/CT again shows prowess for prostate cancer
By Wayne Forrest
Prostate-specific membrane antigen (PMSA)-PET/CT could become the primary modality approach in confirming the extent of prostate cancer and the most efficient way to direct patients to the most appropriate treatment, according to a study published on 22 March in Lancet.
March 25, 2020
2019 05 03 20 23 2154 Prostate 3 D 400
Previous Page
Page 7 of 22
Next Page